Adial Begin Period Cash Flow vs Other Non Cash Items Analysis
| ADIL Stock | USD 1.09 0.01 0.91% |
Adial Pharmaceuticals financial indicator trend analysis is way more than just evaluating Adial Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Adial Pharmaceuticals is a good investment. Please check the relationship between Adial Pharmaceuticals Begin Period Cash Flow and its Other Non Cash Items accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
Begin Period Cash Flow vs Other Non Cash Items
Begin Period Cash Flow vs Other Non Cash Items Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Adial Pharmaceuticals Begin Period Cash Flow account and Other Non Cash Items. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Adial Pharmaceuticals' Begin Period Cash Flow and Other Non Cash Items is 0.46. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Other Non Cash Items in the same time period over historical financial statements of Adial Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Adial Pharmaceuticals' Begin Period Cash Flow and Other Non Cash Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Adial Pharmaceuticals are associated (or correlated) with its Other Non Cash Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Non Cash Items has no effect on the direction of Begin Period Cash Flow i.e., Adial Pharmaceuticals' Begin Period Cash Flow and Other Non Cash Items go up and down completely randomly.
Correlation Coefficient | 0.46 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Other Non Cash Items
Most indicators from Adial Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adial Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.At this time, Adial Pharmaceuticals' Enterprise Value Over EBITDA is quite stable compared to the past year. Enterprise Value Multiple is expected to rise to 0.03 this year, although the value of Selling General Administrative will most likely fall to about 5.1 M.
| 2021 | 2023 | 2024 (projected) | Depreciation And Amortization | 55.1K | 648.6 | 616.17 | Interest Income | 6.5K | 106.2K | 111.6K |
Adial Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Adial Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Adial Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 7.7M | 5.5M | 7.5M | 5.7M | 4.7M | 4.4M | |
| Total Current Liabilities | 539.1K | 1.5M | 2.7M | 1.8M | 653.1K | 1.1M | |
| Total Stockholder Equity | 7.1M | 4.0M | 3.5M | 3.3M | 4.1M | 3.1M | |
| Net Tangible Assets | 4.4M | 7.1M | 4.0M | 2.8M | 3.2M | 2.7M | |
| Net Debt | (6.8M) | (4.4M) | (5.8M) | (3.8M) | (2.8M) | (3.0M) | |
| Retained Earnings | (20.6M) | (31.5M) | (50.9M) | (63.7M) | (68.8M) | (65.4M) | |
| Accounts Payable | 190.2K | 648.7K | 286.2K | 276.4K | 127.4K | 121.0K | |
| Cash | 6.8M | 4.4M | 6.1M | 4.0M | 2.8M | 3.4M | |
| Non Current Assets Total | 6.2K | 355.6K | 1.0M | 952.9K | 1.5M | 1.6M | |
| Non Currrent Assets Other | 6.7K | 0.0 | 350K | 455K | 1.5M | 1.6M | |
| Cash And Short Term Investments | 6.8M | 4.4M | 6.1M | 4.0M | 2.8M | 3.4M | |
| Common Stock Total Equity | 3.3K | 6.9K | 10.4K | 14.4K | 13.0K | 12.3K | |
| Common Stock Shares Outstanding | 394.1K | 498.5K | 743.5K | 1.1M | 1.4M | 1.5M | |
| Liabilities And Stockholders Equity | 7.7M | 5.5M | 7.5M | 5.7M | 4.7M | 4.4M | |
| Capital Surpluse | (596.8K) | 16.5M | 27.8M | 35.5M | 40.8M | 42.9M | |
| Other Current Assets | 359.5K | 734.7K | 399.4K | 778.1K | 371.6K | 370.5K | |
| Total Liab | 539.1K | 1.5M | 4.0M | 2.5M | 653.1K | 620.4K | |
| Total Current Assets | 7.7M | 5.1M | 6.5M | 4.8M | 3.2M | 3.9M | |
| Intangible Assets | 6.2K | 5.6K | 460.0K | 459.5K | 3.9K | 3.7K | |
| Common Stock | 10.4K | 14.4K | 20.9K | 26.7K | 1.7K | 1.6K | |
| Non Current Liabilities Total | 190.2K | 648.7K | 1.2M | 665.4K | 437.0 | 415.15 | |
| Other Stockholder Equity | 27.8M | 35.5M | 54.4M | 66.9M | 72.9M | 43.0M | |
| Net Invested Capital | 7.1M | 4.0M | 3.5M | 3.3M | 3.8M | 4.0M | |
| Net Working Capital | 7.1M | 3.6M | 3.7M | 3.0M | 3.4M | 3.8M | |
| Capital Stock | 10.4K | 14.4K | 20.9K | 26.7K | 30.7K | 17.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.94) | Return On Assets (1.04) | Return On Equity (3.21) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.